Leo Aubert
Overview
Explore the profile of Leo Aubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van den Bossche V, Vignau J, Vigneron E, Rizzi I, Zaryouh H, Wouters A, et al.
Nat Commun
. 2025 Jan;
16(1):1237.
PMID: 39890801
Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent...
2.
Glowacka K, Ibanez S, Renoult O, Vermonden P, Giolito M, Ozkan K, et al.
Nat Commun
. 2024 Nov;
15(1):10107.
PMID: 39572570
Cancer cells in acidic tumor regions are aggressive and a key therapeutic target, but distinguishing between acid-exposed and hypoxic cells is challenging. Here, we use carbonic anhydrase 9 (CA9) antibodies...
3.
Bordeleau M, Audemard E, Metois A, Theret L, Lisi V, Farah A, et al.
Cell Rep
. 2024 Jun;
43(6):114260.
PMID: 38838225
Immunotherapy remains underexploited in acute myeloid leukemia (AML) compared to other hematological malignancies. Currently, gemtuzumab ozogamicin is the only therapeutic antibody approved for this disease. Here, to identify potential targets...
4.
Aubert L, Bastien E, Renoult O, Guilbaud C, Ozkan K, Brusa D, et al.
EMBO Rep
. 2024 Feb;
25(3):1469-1489.
PMID: 38366255
Tumor acidosis is associated with increased invasiveness and drug resistance. Here, we take an unbiased approach to identify vulnerabilities of acid-exposed cancer cells by combining pH-dependent flow cytometry cell sorting...
5.
Goyette M, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault M, et al.
Cell Rep
. 2023 Dec;
42(12):113604.
PMID: 38100352
No abstract available.
6.
Gress V, Roussy M, Boulianne L, Bilodeau M, Cardin S, El-Hachem N, et al.
Blood Adv
. 2023 Sep;
8(1):112-129.
PMID: 37729615
Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted, and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery...
7.
Trouvilliez S, Cicero J, Leveque R, Aubert L, Corbet C, Van Outryve A, et al.
J Exp Clin Cancer Res
. 2022 Mar;
41(1):110.
PMID: 35346305
Background: CD44 is a multifunctional membrane glycoprotein. Through its heparan sulfate chain, CD44 presents growth factors to their receptors. We have shown that CD44 and Tropomyosin kinase A (TrkA) form...
8.
Aubert L, Nandagopal N, Roux P
Mol Cell Oncol
. 2020 Nov;
7(6):1822123.
PMID: 33235918
KRAS-driven cancers acquire profound metabolic dependencies that are intimately linked to tumor growth. Our work revealed that colorectal cancers that harbor KRAS mutations are addicted to copper metabolism. This adaptation...
9.
Aubert L, Nandagopal N, Steinhart Z, Lavoie G, Nourreddine S, Berman J, et al.
Nat Commun
. 2020 Jul;
11(1):3701.
PMID: 32709883
Despite its importance in human cancers, including colorectal cancers (CRC), oncogenic KRAS has been extremely challenging to target therapeutically. To identify potential vulnerabilities in KRAS-mutated CRC, we characterize the impact...
10.
Nourreddine S, Lavoie G, Paradis J, Ben El Kadhi K, Meant A, Aubert L, et al.
Cell Rep
. 2020 May;
31(7):107660.
PMID: 32433969
In human cells, the expression of ∼1,000 genes is modulated throughout the cell cycle. Although some of these genes are controlled by specific transcriptional programs, very little is known about...